# AVID100 in Advanced Epithelial Carcinomas

> **NCT03094169** · PHASE1,PHASE2 · TERMINATED · sponsor: **Formation Biologics** · enrollment: 49 (actual)

## Conditions studied

- Solid Tumor, Adult
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AVID100 IV

## Key facts

- **NCT ID:** NCT03094169
- **Lead sponsor:** Formation Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-01
- **Primary completion:** 2020-11-28
- **Final completion:** 2021-01-30
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03094169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03094169, "AVID100 in Advanced Epithelial Carcinomas". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03094169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*